CytoMed Therapeutics (GDTC) Cash & Current Investments (2021 - 2025)

CytoMed Therapeutics has reported Cash & Current Investments for 5 years, with the latest figure at $1.6 million in Q4 2025.

• Quarterly Cash & Current Investments fell 56.73% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (down 56.73% YoY) and the FY2025 annual result came in at $1.6 million, down 56.89% from the prior year.
• Cash & Current Investments eased to $1.6 million in Q4 2025 per GDTC's latest filing, from $4.7 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $10.4 million in Q2 2023 and troughed at $1.1 million in Q4 2022.
• A 5-year average of $4.6 million and a median of $3.7 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments jumped 485.32% in 2023, then slumped 56.73% in 2025.
• Over 5 years, Cash & Current Investments stood at $1.9 million in 2021, then plunged by 38.53% to $1.1 million in 2022, then surged by 485.32% to $6.7 million in 2023, then tumbled by 43.92% to $3.7 million in 2024, then slumped by 56.73% to $1.6 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $1.6 million, $4.7 million, and $3.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.